کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3361434 | 1591895 | 2006 | 4 صفحه PDF | دانلود رایگان |

Among 1429 Escherichia coli isolates collected as part of the SENTRY Antimicrobial Surveillance Program (2004) from 30 North American medical centres, 65 (4.5%) were screen-positive for an extended-spectrum β-lactamase (ESBL). Among the strains with a negative ESBL confirmatory test (n = 26; clavulanic acid inhibition), a CMY-2 enzyme was detected in 13 isolates (50.0%), FOX-5 in 3 isolates (11.5%) and DHA-1 in 1 isolate (3.8%). These AmpC-producing E. coli were cephamycin (cefoxitin)-resistant but susceptible to cefepime (minimum inhibitory concentration (MIC) ≤0.12–4 mg/L). Clearly, the ESBL tests recommended by the Clinical and Laboratory Standards Institute identify only a fraction of E. coli with elevated β-lactam MIC values as ESBL-producing strains; the majority of the remaining strains would be potentially responsive to some other β-lactams, directed by accurately performed and interpreted susceptibility methods.
Journal: International Journal of Antimicrobial Agents - Volume 28, Issue 6, December 2006, Pages 578–581